127 related articles for article (PubMed ID: 37862797)
21. Primary mixed lymphoepithelioma-like carcinoma and intra-hepatic cholangiocarcinoma: a case report and review of literature.
Henderson-Jackson E; Nasir NA; Hakam A; Nasir A; Coppola D
Int J Clin Exp Pathol; 2010 Aug; 3(7):736-41. PubMed ID: 20830246
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features of 11 Epstein-Barr virus-associated intrahepatic cholangiocarcinoma at a single center in China.
Sun K; Xu S; Wei J; Wang B; Owusu-Ansah KG; Wang W; Wu J; Zheng S
Medicine (Baltimore); 2016 Oct; 95(40):e5069. PubMed ID: 27749575
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.
Li XH; Zhao CY; Zhou EL; Lin XJ
BMC Cancer; 2022 Nov; 22(1):1159. PubMed ID: 36357848
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
[TBL] [Abstract][Full Text] [Related]
26. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
[TBL] [Abstract][Full Text] [Related]
27. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
28. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic Cholangiocarcinoma With Lymphoepithelioma-like Carcinoma Components Not Associated With Epstein-Barr Virus: Report of a Case.
Aosasa S; Maejima T; Kimura A; Nishiyama K; Edo H; Shinmoto H; Kaji T; Ogata S; Hatsuse K; Hase K; Yamamoto J
Int Surg; 2015 Apr; 100(4):689-95. PubMed ID: 25875552
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
33. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
Tsai JH; Liau JY; Lee CH; Jeng YM
Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
[TBL] [Abstract][Full Text] [Related]
34. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic cholangiocarcinoma with lymphoepithelioma-like carcinoma component.
Huang Y; Tsung JS; Lin CW; Cheng TY
Ann Clin Lab Sci; 2004; 34(4):476-80. PubMed ID: 15648792
[TBL] [Abstract][Full Text] [Related]
36. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
[TBL] [Abstract][Full Text] [Related]
37. Clonal Epstein-Barr virus associated cholangiocarcinoma with lymphoepithelioma-like component.
Hsu HC; Chen CC; Huang GT; Lee PH
Hum Pathol; 1996 Aug; 27(8):848-50. PubMed ID: 8760021
[TBL] [Abstract][Full Text] [Related]
38. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
40. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]